TargetBeta
EDNRA
endothelin receptor type A · also ET-A, ETA-R, hET-AR · Endothelin receptors
5 programs in company-led studies act on EDNRA, from 5 companies: 3 in phase 3, 2 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| sparsentanrule | Travere Therapeutics | phase 4 | 92 running | AGTR1 | ChEMBL |
| Bosentanrule | Johnson & Johnson | phase 4 | 370 running | EDNRB | ChEMBL |
| Atrasentanrule | Novartis | phase 3 | 154 running | – | ChEMBL |
| zibotentan | AstraZeneca | phase 3 | 232 running | – | a judged reading |
| aprocitentanrule | Idorsia Pharmaceuticals | phase 3 | 141 running | EDNRB | ChEMBL |
Conditions their studies are in
- Glomerulonephritis, IGA, 2 programs
- Hypertension, 2 programs
- Kidney Diseases, 2 programs
- Prostatic Neoplasms, 2 programs
- Renal Insufficiency, 2 programs
- Renal Insufficiency, Chronic, 2 programs
- Diabetic Nephropathies, 1 program
- digital ulcers, 1 program
- Essential Hypertension, 1 program
- Glomerulosclerosis, Focal Segmental, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Feb 18, 2027zibotentan · AstraZeneca · phase 3 · NCT06087835
- Mar 2027sparsentan · Travere Therapeutics · phase 4 · NCT07219121
- Apr 14, 2028Atrasentan · Novartis · phase 3 · NCT04573478
- Dec 28, 2029aprocitentan · Idorsia Pharmaceuticals · phase 3 · NCT07635914
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.